SALT LAKE CITY, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that an abstract has been selected for oral presentation at the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors being held October 22-24, 2009 in New Orleans, LA. The presentation will disclose new findings concerning Azixa(TM), a Myriad Pharmaceuticals drug candidate being developed as a treatment for recurrent glioblastoma multiforme (GBM) and metastatic melanoma. The SNO presentation will include data relating to the use of Azixa as a potential monotherapy and in potential combination with bevacizumab (Avastin(R)).
